Creates provisions relating to testing for diagnosis of uterine cancer

HB 2127 requires healthcare providers to perform a p53 test on all abnormal uterine tissue samples (endometrial samples) collected for diagnosis. This test, which detects protein abnormalities linked to cancer severity, must be done alongside any other existing diagnostic tests. The bill directly affects patients diagnosed with abnormal uterine tissue and their healthcare providers, mandating this specific test to improve diagnosis and treatment planning for uterine cancer. It does not change existing testing requirements but adds the p53 test as a standard step for these cases.